

# Food & Function

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1 Effect of taurine in chronic alcoholic patients

2

3 You-Liang Hsieh<sup>1</sup>, Yen-Hung Yeh<sup>2,3,\*</sup>, Ya-Ting Lee<sup>4</sup>, Chih-Yang Huang<sup>1,5,6</sup>

4

5 *1. Department of Health and Nutrition Biotechnology, Asia University, Taichung, Taiwan, R.O.C.*

6 *2. School of Health Diet and Industry Management, Chung Shan Medical University, Taichung,*

7 *Taiwan, R.O.C.*

8 *3. Department of Nutrition, Chung Shan Medical University Hospital, Taichung, Taiwan, R.O.C.*

9 *4. Department of Beauty Science, National Taichung University of Science and Technology, Taichung,*

10 *Taiwan, R.O.C.*

11 *5. Graduate Institute of Basic Medical Science, China Medical University, Taichung, Taiwan, R.O.C.*

12 *6. Department of Chinese Medicine, China Medical University Hospital, Taichung, Taiwan, R.O.C.*

13

14

15

16

17

18 Running Title: Taurine on alcoholic patients

19

20

21

22

23 Corresponding author:

24

25 \* Corresponding author. Tel.: +886-4-24730022

26 E-mail address: yhyeh@csmu.edu.tw (Y. H. Yeh).

27

28 **Abstract**

29

30 A study was undertaken to investigate the dietary effect of taurine in chronic  
31 alcoholic patients. The 30 chronic alcoholic patients with 2 to 5 times over normal  
32 activities of aspartate transaminase (AST) or alanine transaminase (ALT) were  
33 selected and equally divided into taurine and control groups. In taurine group, each  
34 patient took 6 g taurine per day divided into 3 times for three months, and then  
35 stopped treatment for 1 month. In control group, patients took placebo without taurine  
36 for 4 months. It was found that AST and ALT activities and levels of cholesterol,  
37 triglyceride (TG), bilirubin, and thiobarbituric acid relative substances (TBARS) of  
38 serum plasma in the taurine group were all decreased, but increased alcohol  
39 dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) activities and serum  
40 vitamins concentrations. Except for level of TG, all of them showed significantly  
41 different after taking taurine for 2 or 3 months. It indicated that taurine plays an  
42 important role in the properties of antioxidation and has some improvements on the  
43 liver test of chronic alcoholic patients.

44

45

46

47

48 *Keywords:* Aspartate transaminase; Antioxidation; Alcoholic patient; Liver test;

49 Taurine

50

51

52

## 53 1. Introduction

54

55 Alcoholic is a disease with powerful negative effects that impact not only the  
56 individual afflicted but also society at large. In the United States, alcoholic is the third  
57 leading cause of death and often leads to other sequela<sup>1</sup>, such as cirrhosis, which are  
58 also leading causes of death<sup>2</sup>. Hepatic, pancreatic, and cardiovascular systems are the  
59 major targets of chronic alcohol abuse and alcoholic, alcoholic hepatitis is the single  
60 most common cause of mortality and morbidity from the liver diseases<sup>3</sup>. Chronic  
61 alcohol abuse is associated with wide-ranging neurological damage, such as Wernicke  
62 encephalopathy, dementia, delirium tremens and peripheral polyneuropathy. However,  
63 this area of inquiry will need to keep pace with the growing level of knowledge on  
64 how to best treat chronic alcoholic. The widespread effects of alcoholic necessitate its  
65 study with the goal of increasing treatment efficacy and thus reducing the cost to  
66 society.

67 In our previous papers, we found that dietary taurine could possess a protective  
68 liver test and detoxification action against oxidized oil and heavy metal induced  
69 injuries<sup>4,5</sup>. Taurine is a sulfur-containing amino acid that conjugates with bile acids in  
70 the liver<sup>6</sup> and an essential amino acid for cat<sup>7</sup>. It is well known that taurine is rich in  
71 fish products, especially in mollusks and fish liver<sup>8</sup>. Its physiological functions  
72 include bile acid conjugation, detoxification, osmoregulation, antioxidation,  
73 preventing lipid peroxidation, cell membrane stabilization, neuromodulation and  
74 calcium flux regulator<sup>9,10</sup>. Taurine is largely obtained from the diet, predominantly  
75 through eggs, meat, and seafood<sup>11</sup>. Additionally, taurine acts as an antioxidant and  
76 plays a role in detoxification, membrane stabilization a comma osmoregulation,  
77 neuromodulation, and brain and in retinal development. According to recent reports

78 by Yang et al.<sup>12</sup> and Chang et al.<sup>13</sup>, taurine can accelerate cholesterol degradation to  
79 form bile acid thus increasing fecal bile acid excretion, and enhancing peroxisome  
80 proliferator-activated receptor- $\alpha$  (PPAR- $\alpha$ ) expression which leads to an increase in  
81 hepatic lipid expenditure in high-fat/cholesterol dietary rodents. Chang et al.<sup>13</sup> also  
82 indicated that supplementing taurine can reduce serum glutamic oxaloacetic  
83 transaminase (GOT) and glutamic pyruvic transaminase (GPT) of high-fat/cholesterol  
84 dietary hamsters. At the same time, increased hepatic self-antioxidant capacities and  
85 decreased lipid peroxidation were also observed in high-fat/cholesterol dietary  
86 hamsters co-treated with taurine, taurine supplementation can lower liver  
87 triacylglycerol levels in alcohol fed rats via the downregulation of fatty acid synthase  
88 (FAS) and malic enzyme (ME) gene expressions and the upregulation of PPAR- $\alpha$   
89 gene expression. Additionally, taurine supplementation also decreases TBARS values  
90 in sera and livers which result in lower hepatic TNF- $\alpha$  level and MMP-9 activity.  
91 Recently, Fang et al.<sup>14</sup> indicated that an acceleration of alcohol metabolism via  
92 upregulating alcohol dehydrogenase (ADH), catalase (CAT), and aldehyde  
93 dehydrogenase (ALDH) activities, less microvesicular steatosis, and necrotic cells in  
94 livers were observed when chronic alcohol-fed rats were supplemented with taurine.  
95 Hence, it prompted us to investigate the dietary effect of taurine on the chronic  
96 alcoholic patients. One of the promising research areas in biomedical science today is  
97 the focus on alcoholic and taurine. This article presents a brief overview of taurine,  
98 the results of taurine studies related to alcoholic. Therefore, it shows how nursing  
99 practice strategies can be derived from biomedical research related to taurine and  
100 alcoholic.

101

## 102 **2. Materials and methods**

103

104 *2.1. Experiment*

105       The 30 alcoholic patients with 2 to 5 times over normal activities of aspartate  
106 transaminase (AST) or alanine transaminase (ALT) were selected and divided into  
107 two groups, taurine group and control group. In taurine group, patients consisted of 8  
108 men and 7 women and their average age and body weight were  $59\pm 13$  years old and  
109  $62\pm 11$  kg, respectively. In control group, patients included each 9 men and 6 women  
110 and their average age and body weight were  $60\pm 12$  years old and  $61\pm 10$  kg,  
111 respectively. This study was carried out in accordance with the Helsinki Declaration  
112 of the World Medical Association and was approved by the University's Ethics  
113 Committee. Written informed consent was obtained from each subject after the study  
114 was explained to them. All patients promised the treatment and then the experiment  
115 was conducted out. In taurine group, each patient took 6 g taurine per day for three  
116 months, and then stopped treatment for 1 month. The daily intake of 6 g taurine was  
117 divided into three parts and given to each patient of taurine group after meal. In  
118 control group, patients took placebo without taurine. Taurine was purchased from  
119 Dokui Chemical Company (Taiwan), its purity was 99.5%. The blood samples of all  
120 patients were collected per month and analyzed for blood characteristics, including  
121 red blood cells (RBC), white blood cells (WBC), hemoglobin (Hb) and platelet, by  
122 using a Cell Hematology Analyzer (DYN 500, Sequoi-Turner, USA). The plasma  
123 samples were collected by centrifugation ( $2,000 \times g$ , 15 min) from blood and  
124 examined for the levels of BUN, creatinine, bilirubin, cholesterol and TG and the  
125 activities of AST and ALT in the plasma were assayed by a Vitalab Selectra (E. Merck,  
126 Germany) with using an enzymatic kit. Serum concentrations of vitamin B<sub>12</sub>, folate  
127 and vitamin B<sub>6</sub><sup>15</sup>, were measured according to established published methods.

128

129 *2.2. Determination of TBARS*

130 Lipid peroxidation level was estimated by measuring thiobarbituric acid reactive  
131 substances (TBARS) according to Buege and Aust<sup>16</sup> and was expressed in terms of  
132 malondialdehyde (MDA) content which is the end product of lipid peroxidation. In  
133 brief, 125  $\mu\text{l}$  of supernatants were homogenized by sonication with 50  $\mu\text{l}$  of TBS, 125  
134  $\mu\text{l}$  of TCA-BHT in order to precipitate proteins and centrifuged ( $1,000 \times g$ , 10 min,  
135  $4^{\circ}\text{C}$ ). 200  $\mu\text{l}$  of obtained supernatant were mixed with 40  $\mu\text{l}$  of HCl (0.6 M) and 160  
136  $\mu\text{l}$  of TBA dissolved in Tris and the mixture was heated at  $80^{\circ}\text{C}$  for 10 min. The  
137 absorbance of the resultant supernatant was read at 530 nm. The amount of TBARS  
138 was calculated by using an extinction coefficient of  $156 \times 10^5 \text{mM}^{-1} \text{cm}^{-1}$ .

139

140 *2.3. Determination of total ADH activity*

141 Total ADH activity was estimated by the photometric method with  
142 p-nitrosodimethylaniline (NDMA) as a substrate<sup>17</sup>. The reaction mixture (2 ml)  
143 contained 1.9 ml of a 26  $\mu\text{M}$  solution of substrate in 0.1 M of sodium phosphate  
144 buffer, pH 8.5 and 0.1 ml of a mixture containing 0.25 M n-butanol and 5 mM NAD.  
145 The reduction of NDMA was monitored at 440 nm.

146

147 *2.4. Determination of total ALDH activity*

148 ALDH activity was measured using the fluorogenic method based on the  
149 oxidation of 6-methoxy-2-naphtaldehyde to the fluorescent 6-methoxy-2 naphtoate<sup>18</sup>.  
150 The reaction mixture contained 60  $\mu\text{l}$  of substrate, 20  $\mu\text{l}$  of 11.4 mM NAD and 2.8 ml  
151 of 50 mM of sodium phosphate buffer, pH 8.5. The mixture contained also 50  $\mu\text{l}$  of a  
152 12 mM solution of 4-methylpyrazole as a specific inhibitor of ADH activity. The

153 fluorescence was read at excitation wavelength 310 and emission wavelength 360 nm.

154

### 155 2.5. Statistical analysis

156 Statistical analysis for differences among patients in the experimental groups was  
157 performed by the 2-way analysis of variance procedure and Duncan's new multiple  
158 range tests. A  $P$  value  $< 0.05$  was considered statistically significant.

159

## 160 3. Results

161

162 After treating with dietary taurine for 3 months, all indicators of blood  
163 characteristics in the alcoholic patients was not affected ( $P > 0.05$ ). The data are  
164 similar to those in control group. The data of blood characteristics in normal people  
165 are as follows:  $4.8-10.8 \times 10^3$  cells/ $\mu\text{l}$  for WBC,  $4.2-6.1 \times 10^6$  cells/ $\mu\text{l}$  for RBC, 14-18  
166 g/dl for Hb and  $130-400 \times 10^3$  cells/ $\mu\text{l}$  for platelet. All data of blood characteristics in  
167 chronic alcoholic patients in taurine and control groups were not different from each  
168 other. It indicates that the blood characteristics of alcoholic patients are the same as  
169 those normal people and dietary taurine supplement can not change them.

170 The dietary effect of taurine on AST, ALT, and bilirubin of chronic alcoholic  
171 patients is shown in Fig. 1. After treating with dietary taurine for 2 months, AST, ALT,  
172 and bilirubin of plasma in the chronic alcoholic patients was significantly decreased  
173 ( $P < 0.05$ ). It was also found that the AST, ALT, and bilirubin of chronic alcoholic  
174 patients in control group are not changed during experimental period.

175 The dietary effect of taurine on BUN and creatinine of chronic alcoholic patients  
176 is shown in Fig. 2. After treating with dietary taurine for 3 months, There was no



177 significant difference ( $P > 0.05$ ) in the concentration on BUN and creatinine in the  
178 plasma among various groups.

179 The dietary effect of taurine on cholesterol and TG level of chronic alcoholic  
180 patients is shown in Fig. 3. After treating with dietary taurine for 3 months,  
181 cholesterol and TG level of plasma in the chronic alcoholic patients was significantly  
182 decreased ( $P < 0.05$ ).

183 The dietary effect of taurine on ADH and ALDH activities of chronic alcoholic  
184 patients is shown in Fig. 4. After treating with dietary taurine for 3 months, ADH and  
185 ALDH activities of plasma in the chronic alcoholic patients was significantly  
186 increased ( $P < 0.05$ ). After stopping treatment at the fourth month, the ADH and  
187 ALDH activity was also elevated. During the experimental period, the ADH and  
188 ALDH activities of chronic alcoholic patients in control group was also not changed.

189 The dietary effect of taurine on TBARS and GSH level of chronic alcoholic  
190 patients is shown in Fig. 5. After treating with dietary taurine for 2 months, TBARS  
191 and GSH level of plasma in the chronic alcoholic patients was significantly decreased  
192 ( $P < 0.05$ ). It indicates that the peroxidation of blood plasma in alcoholic patients  
193 could be availably ameliorated by dietary taurine.

194 The dietary effect of taurine on vitamin B<sub>12</sub>, folate and vitamin B<sub>6</sub> of chronic  
195 alcoholic patients is shown in Fig. 6. After treating with dietary taurine for 2 months,  
196 vitamin B<sub>12</sub>, folate and vitamin B<sub>6</sub> of plasma in the chronic alcoholic patients was  
197 significantly increased ( $P < 0.05$ ). Since stopping treatment at the fourth month,  
198 vitamin B<sub>12</sub>, folate and vitamin B<sub>6</sub> of plasma in the chronic alcoholic was not elevated.  
199 However, the variation of vitamin B<sub>12</sub>, folate and vitamin B<sub>6</sub> of plasma in the chronic

200 alcoholic patients without taurine supplement was not found during the experimental  
201 period. It indicates that the vitamins of blood plasma in alcoholic patients could be  
202 availably ameliorated by dietary taurine.

203

#### 204 **4. Discussion**

205

206 In this study, the blood characteristics, activities of ALT, AST, ADH, and ALDH  
207 and levels of bilirubin, TG, cholesterol and TBARS in the plasma of chronic alcoholic  
208 patients without supplement of taurine during experimental period of 4 months were  
209 not changed. However the chronic alcoholic patients were treated with dietary taurine,  
210 the clinical symptoms including ALT, AST, ADH, and ALDH activities and bilirubin,  
211 TG, cholesterol and TBARS levels were significantly affected. ALT and AST activities  
212 in plasma serve as biomarkers for liver tests<sup>19</sup>. The value in normal human is as  
213 follows: 10-40 U/l for ALT and 5-45 U/l for AST. The ALT and AST activities in  
214 chronic alcoholic patients were higher than those of normal human. Among them,  
215 ALT activity was higher than AST activity in the chronic alcoholic patients. It means  
216 that alcoholic might injure liver test. Taurine significantly reduced the enzymatic  
217 activities of ALT and AST in the plasma of chronic alcoholic patients, indicating that  
218 the liver injury by alcoholic could be ameliorated by taurine. Wright et al.<sup>20</sup> pointed  
219 out that the function of taurine for preserving liver cells was presented by the high  
220 content of taurine in cell membrane.

221 Alcohol is mainly metabolized by ADH in cytosol, CYP2E1 in endoplasmic  
222 reticulum, and CAT in peroxisomes to form acetaldehyde, and further catabolized to  
223 acetic acid by ALDH<sup>21</sup>. However, during the alcohol metabolism by CYP2E1 the  
224 reactive oxygen species (ROS) also generates and increases the lipid peroxidation, i.e.

225 MDA in the liver<sup>22-24</sup>. However, the level of TBARS in the plasma is an additional  
226 indicator of liver injury. The level of TBARS in the plasma of alcoholic patients was  
227 significantly reduced when the patients were treated with the supplement of taurine.  
228 This result is the same as that reported previously<sup>4,25</sup>. Therefore, it is reasonable to  
229 assume that taurine may act as a good scavenger in reducing lipid peroxidation  
230 induced by drugs<sup>26</sup>, heavy metals<sup>5</sup> and oxidized oil<sup>4</sup>.

231 The levels of TG and cholesterol in the plasma of chronic alcoholic patients  
232 were not higher than those of normal human (120-200 mg/dl for cholesterol, 35-170  
233 mg/dl for TG). However, the levels of TG and cholesterol in the plasma of alcoholic  
234 patients were significantly reduced when the patients were treated with the  
235 supplement of taurine. These results are the same as those reported previously<sup>27-29</sup>.  
236 The reduction of TG and cholesterol levels in the plasma may induce the decrease of  
237 lipid peroxidation, resulting in inhibiting production of TBARS. Judging from above  
238 data taurine plays an important role in the properties of antioxidation and has some  
239 improvements on the liver test of chronic alcoholic patients. Hence, taurine is a  
240 valuable dietary nutrient for chronic alcoholic patients.

241 The level of GSH in the liver of rats was reduced by chronic alcoholic patients,  
242 which was similar to that of other report<sup>30,31</sup>. In our previous study, the level of GSH  
243 in the liver of rats was raised significantly when the rats were fed with the supplement  
244 of taurine<sup>4</sup>.

245 Alcohol has been known for a long time to interfere with the absorption of  
246 several nutrients, including vitamins, and to lead to mucosal damage of the upper  
247 small intestine, thereby contributing to the qualitative and quantitative malnutrition  
248 frequently observed in alcoholics<sup>32,33</sup>. Therefore, taurine is a safe dietary nutrient and  
249 an effective hepatoprotective agent to benefit chronic alcoholic patients.

250

251 **Acknowledgement**

252

253 This study was supported by the Asia University (100-A-06) and Chung Shan  
254 Medical University (CSMU-INT-102-12).

255

256 **References**

257

- 258 1. U.S. Department of Health and Human Services, National Institute on Alcohol  
259 Abuse and Alcoholism. 10th Special Report to the U.S. Congress on Alcohol and  
260 Health: Highlights from Current Research from the Secretary of Health and  
261 Human Services. 2000.
- 262 2. Carson VB, Arnold EN. The journey anesthetized by substance use. Mental health  
263 nursing: The nurse patient journey. Philadelphia: Saunders. 1996.
- 264 3. Lankisch PG, Banks PA. Pancreatitis. Berlin/Heidelberg/New York: Springer-Verlag.  
265 1998.
- 266 4. Yeh YH, Chen MH, Lee YT, Hsieh HS, Hwang DF. Effect of taurine on toxicity of  
267 oxidized cholesterol and oxidized fish oil in rats. *J Food Drug Anal* 2008; 16:  
268 76-85.
- 269 5. Yeh YH, Lee YT, Hsieh YL, Hwang DF. Dietary taurine reduces zinc induced  
270 toxicity in male Wistar rats. *J Food Sci* 2011; 76: 90-98.
- 271 6. Jacobsen JG, Smith LHJ. Biochemistry and physiology of taurine and taurine  
272 derivatives. *Physiol Rev* 1968; 48: 425-511.
- 273 7. Knopf K, Sturman JA, Armstrong M, Hayes KC. Taurine an essential nutrient for  
274 the cat. *J Nutr* 1978; 108: 773-778.

- 275 8. Sakaguchi M, Urata M. Seasonal variations of free amino acids in oyster whole  
276 body and adductor muscle. *Nippon Suisan Gakkaishi* 1989; 55: 2037-2041.
- 277 9. Balkan J, Kanbagli O, Aykac-Toker G, Uysal B. Taurine treatment reduces hepatic  
278 lipids and oxidative stress in chronically ethanol-treated rats. *Biol Pharm Bull*  
279 2002; 25: 1231-1233.
- 280 10. Nandhini AT, Balakrishnan SD, Anuradha CV. Response of liver antioxidant  
281 system to taurine in rats fed high fructose diet. *Indian J Exp Biol* 2002; 40:  
282 1016-1019.
- 283 11. Kadam SU, Prabhasankar P. Marine foods as functional ingredients in bakery and  
284 pasta products. *Food Res Int* 2010; 43: 1975-1980.
- 285 12. Yang SF, Tzang BS, Yang KT, Hsiao YC, Chang YY, Chan CH, Fu SG, Chen YC.  
286 Taurine alleviates dyslipidemia in hamsters fed a high-fat/cholesterol diet. *Food*  
287 *Chem* 2010; 120: 156-162.
- 288 13. Chang YY, Chou CH, Chiu CH, Yang KT, Lin YL, Weng WL, Chen YC.  
289 Preventive effects of taurine on development of hepatic steatosis induced by a  
290 high-fat/cholesterol-dietary habit. *J Agric Food Chem* 2011; 59: 450-457.
- 291 14. Fang YJ, Chiu CH, Chang YY, Chou CH, Lin HW, Chen MF, Chen YC. Taurine  
292 ameliorates alcoholic steatohepatitis via enhancing self-antioxidant capacity and  
293 alcohol metabolism. *Food Res Int* 2011; 44: 3105-3110.
- 294 15. Boers GHJ, Smals AGH, Trijbels FJM. Heterozygosity for homocystinuria in  
295 premature peripheral and cerebral occlusive arterial disease. *N Engl J. Med* 1985;  
296 313: 709-715.
- 297 16. Buege JA, Aust SD. Microsomal lipid peroxidation. *Methods Enzymol* 1984; 105:  
298 302-310.
- 299 17. Skursky L, Kovar J, Stachova M. A sensitive assay for alcohol dehydrogenase

- 300 activity in blood serum. *Anal Biochem* 1979; 89: 65-71.
- 301 18. Jelski W, Zalewski B, Chrostek L, Szmitkowski M. The activity of class I, II, III  
302 and IV of alcohol dehydrogenase (ADH) isoenzymes and aldehyde  
303 dehydrogenase (ALDH) in the colorectal cancer. *Dig Dis Sci* 2004; 49: 977-981.
- 304 19. Ronald L, Koretz MD. Chronic hepatitis: Science and superstition. In: Gitnick, G.  
305 (Ed.), *Current Hepatology*. Chicago: Mosby-Year. 1992.
- 306 20. Wright CR, Tallan HH, Lin YY. Taurine: Biological update. *Ann Rev Biochem*  
307 1986; 55: 427-453.
- 308 21. Lieber CS. Biochemical factors in alcoholic liver disease. *Semin. Liver Dis* 1993;  
309 13: 136-153.
- 310 22. Gill K, Amit Z, Smith BR. The regulation of alcohol consumption in rats: The role  
311 of alcohol-metabolising enzymes-Catalase and aldehyde dehydrogenase. *Alcohol*  
312 1996; 13: 347-353.
- 313 23. Pari L, Suresh A. Effect of grape (*Vitis vinifera* L.) leaf extract on alcohol induced  
314 oxidative stress in rats. *Food Chem Toxicol* 2008; 46: 1627-1634.
- 315 24. Song Z, Zhou Z, Chen T, Hill D, Kang J, Barve S, McClain C.  
316 S-adenosylmethionine (SAME) protects against acute alcohol induced  
317 hepatotoxicity in mice. *J Nutr Biochem* 2003; 14: 591-594.
- 318 25. Tadolini B, Gianfrance P, Gavino GP, Federico B, Flavia F. Effect of taurine and  
319 hypotaurine on lipid peroxidation. *Biochem Biophys Res Commun* 1995; 213:  
320 820-826.
- 321 26. Waters E, Wag JH, Redmond HP, Wu QD, Kay E, Bouchier HD. Role of taurine in  
322 preventing acetaminophen-induced hepatic injury in the rat. *Gastrointest. Liver*  
323 *Physiol* 2001; 280: 1274-1279.
- 324 27. Huang CJ, Chuan NN, Sheu CT. The effects of taurine supplementation on plasma

- 325 and liver cholesterol level of rats fed diets containing high cholesterol food. *J*  
326 *Chin Nutr Soc* 1988; 13: 11-22.
- 327 28. Mizushima S, Nara Y, Sawamura M, Yamori Y. Effects of oral taurine  
328 supplementation on lipids and sympathetic nerve tone. *Adv Exp Med Biol* 1996;  
329 403: 615-622.
- 330 29. Dawson R, Liu S, Eppler B, Patterson T. Effects of dietary taurine  
331 supplementation or deprivation in aged male Fisher 344 rats. *Mech. Ageing Dev*  
332 1999; 17: 73-91.
- 333 30. Azzalis LA, Junqueira VBC, Simon K, Giavarotti L, Silva MA, Kogare M, Simizu  
334 K, Barros SBM, Fraga C, Porta EA. Prooxidant and antioxidant hepatic factors in  
335 rats chronically fed an ethanol regimen and treated with an acute dose of lindane.  
336 *Free Radical Biol Med* 1995; 19: 147-159.
- 337 31. Bosch-Morell F, Colell A, Fernández-Checa JC, Marín M, Romero FJ. Chronic  
338 alcohol treatment promotes oxidative stress in rat peripheral nerve. Beneficial  
339 effects of antioxidants. *Pathophysiology* 1998; 5: 82.
- 340 32. Bode JC, Bode C. Alcohol malnutrition and the gastrointestinal tract. In Watson  
341 RR & Watzl B (eds) *Nutrition and Alcohol*. Boca Raton, FL: CRC Press. 1990.
- 342 33. Mezey E. Effect of ethanol on intestinal morphology, metabolism, and function. In  
343 Seitz HK & Kommerell B (eds) *Alcohol Related Diseases in Gastroenterology*.  
344 Berlin: Springer.1985.
- 345
- 346
- 347
- 348
- 349

350

351

352

353 Legends for Figures:

354

355 Fig. 1. Effect of taurine on the AST, ALT, and bilirubin of serum plasma in chronic  
356 alcoholic patients after 4 months. Data represent significantly different when  
357 the letters are different ( $p<0.05$ ). Taurine group: patients took 6 g taurine per  
358 day for three months. Control group: patients took placebo without taurine. a-b:  
359 values in the same week with different superscript are significantly different at  
360  $P<0.05$  by ANOVA (n=30).

361 Fig. 2. Effect of taurine on the BUN and creatinine of serum plasma in chronic  
362 alcoholic patients after 4 months. Taurine group: patients took 6 g taurine per  
363 day for three months. Control group: patients took placebo without taurine. a:  
364 values in the same week with different superscript are significantly different at  
365  $P>0.05$  by ANOVA (n=30).

366 Fig. 3. Effect of taurine on the cholesterol and triglyceride of serum plasma in chronic  
367 alcoholic patients after 4 months. Taurine group: patients took 6 g taurine per  
368 day for three months. Control group: patients took placebo without taurine. a-b:  
369 values in the same week with different superscript are significantly different at  
370  $P<0.05$  by ANOVA (n=30).

371 Fig. 4. Effect of taurine on the ADH and ALDH of serum plasma in chronic alcoholic  
372 patients after 4 months. Taurine group: patients took 6 g taurine per day for  
373 three months. Control group: patients took placebo without taurine. a-b: values  
374 in the same week with different superscript are significantly different at  
375  $P<0.05$  by ANOVA (n=30).

376 Fig. 5. Effect of taurine on the TBARS and GSH of serum plasma in chronic alcoholic  
377 patients after 4 months. Taurine group: patients took 6 g taurine per day for  
378 three months. Control group: patients took placebo without taurine. a-b: values  
379 in the same week with different superscript are significantly different at  
380  $P<0.05$  by ANOVA (n=30).

381 Fig. 6. Effect of taurine on the vitamin B<sub>12</sub>, vitamin B<sub>6</sub>, and folate of serum plasma in  
382 chronic alcoholic patients after 4 months. Taurine group: patients took 6 g



383 taurine per day for three months. Control group: patients took placebo without  
 384 taurine. a-b: values in the same week with different superscript are  
 385 significantly different at  $P < 0.05$  by ANOVA (n=30).  
 386





Fig. 1. Yeh et al.

387

388

389

390



391  
392


393

Fig. 2. Yeh et al.

394

395

396




397

Fig. 3. Yeh et al.

398

399

400




401  
402

Fig. 4. Yeh et al.

403

404

405



406

407

Fig. 5. Yeh et al.

408

409




Fig. 6. Yeh et al.

410

411

412

413

414